During National Nurses Month, SCA Pharma recognizes the front-line providers whose work has been critical during the pandemic
SCA Pharma is proud to honor these essential front-line providers during National Nurses Month.
WINDSOR, CONN. (July 27, 2021) – SCA Pharma, which provides high-quality sterile admixture services to hospitals and health-care facilities nationwide, has named Scott Luce as Chief Executive Officer.
Luce brings to SCA Pharma more than three decades of pharmaceutical industry leadership experience. He joined SCA Pharma earlier this year as Chief Commercial Officer and most recently served as an operating partner with The Vistria Group. Previously, he held numerous leadership roles in general management, sales and marketing, and business development with both Abbott and Baxter.
Luce succeeds Milton Boyer, who led the company through several critical milestones, including the opening of a new manufacturing facility, and delivering high-demand pharmaceuticals to hospitals during the COVID-19 pandemic.
“As sterile outsourcing continues to gain traction within the pharmaceutical landscape, SCA Pharma’s key differentiator will be our continuous commitment to best-in-class quality and manufacturing,” Luce said. “SCA Pharma is well-positioned for growth and innovation, and I take the company reins excited to leverage our relentless focus on quality and the customer experience.”
SCA Pharma is a nationally recognized leader in the FDA 503B outsourcing industry, specializing in providing the highest quality sterile admixture services and pre-filled syringes to hospital and health-care facility pharmacies. The company serves all therapeutic areas of pharmacy — including critical care, labor and delivery, anesthesia, and pain management — and maintains a wide portfolio of products, including ready-to-use and drug-shortage medications.
Luce said his priorities as CEO include serving new customer segments and fulfilling the company’s ambitious construction plan to expand capacity on behalf of customers and patients. The expansion will increase SCA Pharma’s physical footprint and introduce significant new automation to enhance scalability.